In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on BioCryst (BCRX – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $5.27.
Abrahams covers the Healthcare sector, focusing on stocks such as SAGE Therapeutics, Biogen, and Incyte. According to TipRanks, Abrahams has an average return of 7.7% and a 49.09% success rate on recommended stocks.
In addition to RBC Capital, BioCryst also received a Buy from JMP Securities’s Jonathan Wolleben in a report issued today. However, on the same day, Barclays maintained a Hold rating on BioCryst (NASDAQ: BCRX).
The company has a one-year high of $8.96 and a one-year low of $4.03. Currently, BioCryst has an average volume of 3.38M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst (BCRX) Company Description:
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
Read More on BCRX:
